EPA079 | Maternal HIV status and risk of infant M. tuberculosis infection | E-poster | HIV and co-infections (TB, viral hepatitis, SARS-CoV2, other) |
EPA080 | Impact of chronic HCV infection on CD4-T cells permissiveness to HIV infection and viral reservoir persistence | E-poster | HIV and co-infections (TB, viral hepatitis, SARS-CoV2, other) |
EPA081 | HPV circulating tumoural DNA as a potential biomarker to monitor anal lesions in HIV-infected men who have sex with men (MSM) | E-poster | HIV and co-infections (TB, viral hepatitis, SARS-CoV2, other) |
EPA082 | Machine learning prediction and phyloanatomic modeling of viral neuroadaptive signatures in the macaque model of human immunodeficiency virus-mediated neuropathology | E-poster | Neuropathogenesis |
EPA083 | Evidence of recurrent selection of mutations commonly found in SARS-CoV-2 variants of concern in viruses infecting immunocompromised patients | E-poster | SARS-Cov2 Viral origins, evolution and diversity |
EPA084 | Effects of COVID-19 on the cytokine background in chronic controlled HIV infection | E-poster | Immune responses to SARS-Cov2 |
EPA085 | Vitamin D supplementation enhances cytotoxic response in patients with severe COVID-19 | E-poster | Immune responses to SARS-Cov2 |
EPA087 | Limited immunogenicity of SARS-CoV-2 vaccine in people living with HIV (PWH) and low nadir CD4 counts | E-poster | SARS-Cov2 vaccines |
EPA088 | Adverse events following COVID-19 vaccination among people with HIV: review of available vaccine safety literature | E-poster | SARS-Cov2 vaccines |
EPA089 | Potent cytotoxic activity against SARS-CoV-2 of CD8+ T cells from individuals with HIV who received complete schedule of COVID-19 vaccines | E-poster | SARS-Cov2 vaccines |